AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22422777 — intervention group
Group type: COMPARATOR
Intervention: GnRH-agonist (intranasal buserelin 600 mg per day starting on Day 21 of the preceding cycle)
Number of subjects: 190
Study 22422777 — intervention group
Group type: COMPARATOR
Intervention: GnRH-agonist (progesterone >1.5 ng/ml)
Number of subjects: 190
Study 22422777 — intervention group
Group type: COMPARATOR
Intervention: GnRH-antagonist (progesterone >1.5 ng/ml)
Number of subjects: 190
Study 20307164 — intervention group
Group type: EXPERIMENTAL
Intervention: K10 'worst month in the past 12 months' version
Number of subjects: 12992
Study 20307164 — intervention group
Group type: COMPARATOR
Intervention: K10 'past month' version
Number of subjects: 12992
Study 18823565 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy interventions
Number of subjects: 0
Study 18823565 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16277137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioural Therapy (CBT) alone
Number of subjects: 65
Study 16277137 — intervention group
Group type: COMPARATOR
Intervention: SSRI antidepressant therapy (fluoxetine) alone
Number of subjects: 65
Study 16277137 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT plus fluoxetine
Number of subjects: 65
Study 11926787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 15
Study 11926787 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 15
Study 9469215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) treatment for 7 weeks and continued for a mean of 55 weeks (range: 24-111 weeks)
Number of subjects: 50
Study 9469215 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution after NT treatment
Number of subjects: 50
Study 9469215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) treatment
Number of subjects: 50
Study 7708855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated optical spectrometer at 807 nm
Number of subjects: 135
Study 7708855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated optical spectrometer
Number of subjects: 135
Study 2652027 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 5% solution for 3 days before surgery
Number of subjects: 40
Study 2652027 — intervention group
Group type: COMPARATOR
Intervention: Neosporin (combination antibiotic ophthalmic solution) for 3 days before surgery
Number of subjects: 40
Study 1183355 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg beta‐methyldigoxin
Number of subjects: 42
Study 1183355 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg digoxin
Number of subjects: 42
Study 30658668 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented feedback during simulator training
Number of subjects: 40
Study 30658668 — intervention group
Group type: COMPARATOR
Intervention: No augmented feedback (Control)
Number of subjects: 40
Study 28661204 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression brace (CB)
Number of subjects: 86
Study 28661204 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up brace (LB)
Number of subjects: 86
Study 28661204 — intervention group
Group type: COMPARATOR
Intervention: Semirigid brace (SB)
Number of subjects: 86
Study 26207902 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy
Number of subjects: 148
Study 26207902 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 148
Study 23453090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive ambulatory blood pressure control (goal 24-hour systolic BP of ≤130 mm Hg)
Number of subjects: 300
Study 23453090 — intervention group
Group type: COMPARATOR
Intervention: Standard ambulatory blood pressure control (goal 24-hour systolic BP of ≤145 mm Hg)
Number of subjects: 300
Study 21946848 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training targeting the affected muscles (SST)
Number of subjects: 42
Study 21946848 — intervention group
Group type: EXPERIMENTAL
Intervention: General fitness training (GFT)
Number of subjects: 42
Study 21946848 — intervention group
Group type: COMPARATOR
Intervention: General health information (REF)
Number of subjects: 42
Study 19169265 — intervention group
Group type: EXPERIMENTAL
Intervention: D-004 (320 mg) capsules administered daily for 6 weeks
Number of subjects: 34
Study 19169265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16507071 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite base (Tetric Flow Chroma) with acid etching and adhesive system (Excite DSC)
Number of subjects: 70
Study 16507071 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite base (Tetric Flow Chroma) with acid etching and adhesive system (Syntac)
Number of subjects: 70
Study 16507071 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite base (Tetric Flow Chroma) with acid etching and adhesive system (Excite)
Number of subjects: 70
Study 16507071 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite base (Tetric Flow Chroma) with adhesive system only (no acid etching)
Number of subjects: 70
Study 16507071 — intervention group
Group type: COMPARATOR
Intervention: Control group without adhesive system or acid etching
Number of subjects: 70
Study 12752542 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive programs with varying fluoride content and contact with dental personnel
Number of subjects: 1165
Study 12752542 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs contributed by the patient and the patient's family
Number of subjects: 1165
Study 17105328 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO(+)) - passive maxillary plates during the first year
Number of subjects: 41
Study 17105328 — intervention group
Group type: COMPARATOR
Intervention: No infant orthopedics (IO(-))
Number of subjects: 41
Study 10393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1-16 mg)
Number of subjects: 0
Study 10393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0
Study 10393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.8 mg)
Number of subjects: 0
Study 10393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg)
Number of subjects: 0
Study 10393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1-2 mg)
Number of subjects: 0
Study 10393475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8654637 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcoital test (PCT)
Number of subjects: 290
Study 8654637 — intervention group
Group type: COMPARATOR
Intervention: Non-postcoital test (non-PCT)
Number of subjects: 290
Study 1852180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric NCEP diet with exercise
Number of subjects: 264
Study 1852180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric NCEP diet
Number of subjects: 264
Study 1852180 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 264
Study 6341944 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b (Hib) capsular polysaccharide vaccine
Number of subjects: 48997
Study 27562219 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen 1 hour before surgery and another 600 mg 6 hours after the first dose
Number of subjects: 117
Study 27562219 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone 1 hour before surgery and another 4 mg 6 hours after the first dose
Number of subjects: 117
Study 27562219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 26916172 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-mg levonorgestrel (LNG-IUD)
Number of subjects: 3755
Study 26916172 — intervention group
Group type: COMPARATOR
Intervention: Copper T 380 A IUD (TCu380A)
Number of subjects: 3755
Study 24766686 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based technology for QOL data collection
Number of subjects: 49
Study 24766686 — intervention group
Group type: COMPARATOR
Intervention: Paper forms for QOL data collection
Number of subjects: 49
Study 22373033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziemer FEMTO LDV femtosecond laser
Number of subjects: 360
Study 22373033 — intervention group
Group type: COMPARATOR
Intervention: Moria M2 mechanical microkeratome
Number of subjects: 360
Study 20818286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 829
Study 20818286 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone treatment (Control)
Number of subjects: 829
Study 20818286 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population with early deterioration
Number of subjects: 829
Study 17156903 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure and warning in upright standing posture
Number of subjects: 30
Study 17156903 — intervention group
Group type: EXPERIMENTAL
Intervention: Stooped standing posture
Number of subjects: 30
Study 17156903 — intervention group
Group type: COMPARATOR
Intervention: Upright standing posture without prior experience or warning
Number of subjects: 30
Study 15718316 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium implant (IM) plus external-beam radiation therapy (EBRT)
Number of subjects: 104
Study 15718316 — intervention group
Group type: COMPARATOR
Intervention: External-beam radiation therapy (EBRT) alone
Number of subjects: 104
Study 12545683 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%)
Number of subjects: 132
Study 12545683 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (0.005%)
Number of subjects: 132
Study 12545683 — intervention group
Group type: COMPARATOR
Intervention: Timolol (0.5%)
Number of subjects: 132
Study 9655717 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg budesonide twice daily
Number of subjects: 84
Study 9655717 — intervention group
Group type: COMPARATOR
Intervention: 100 microg budesonide twice daily
Number of subjects: 84
Study 7640129 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine gel 1 g (4% w/w)
Number of subjects: 42
Study 7640129 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel 1 g
Number of subjects: 42
Study 2671191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical mitral valves
Number of subjects: 1281
Study 2671191 — intervention group
Group type: COMPARATOR
Intervention: Biological mitral valves
Number of subjects: 1281
Study 2671191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical aortic valves
Number of subjects: 1281
Study 2671191 — intervention group
Group type: COMPARATOR
Intervention: Biological aortic valves
Number of subjects: 1281
Study 30500926 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal rehabilitation (RR) programme completion (attended >50% planned sessions)
Number of subjects: 757
Study 30500926 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal rehabilitation (RR) programme success (improvement in incremental shuttle walk test (ISWT) by ≥50 m)
Number of subjects: 757
Study 30500926 — intervention group
Group type: COMPARATOR
Intervention: Non-completers of RR
Number of subjects: 757
Study 30500926 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ISWT of >50 m
Number of subjects: 757
Study 27717126 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus liraglutide
Number of subjects: 33
Study 27717126 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus placebo
Number of subjects: 33
Study 25650733 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training three times per week with 25-30% caloric restriction
Number of subjects: 239
Study 25650733 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training three times per week with 25-30% caloric restriction
Number of subjects: 239
Study 25650733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance and strength training three times per week with 25-30% caloric restriction
Number of subjects: 239
Study 25650733 — intervention group
Group type: EXPERIMENTAL
Intervention: Following the American College of Sports Medicine physical activity guidelines for body weight loss with 25-30% caloric restriction
Number of subjects: 239
Study 24930512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized methacholine inhalation (0.39 to 25 mg/ml)
Number of subjects: 15
Study 24930512 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%; control)
Number of subjects: 15
Study 23071344 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage intervention (weekly 45-minute massages for 4 weeks)
Number of subjects: 70
Study 23071344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage intervention)
Number of subjects: 70
Study 21288052 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg
Number of subjects: 14
Study 21288052 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg
Number of subjects: 14
Study 17999217 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition
Number of subjects: 134
Study 17999217 — intervention group
Group type: COMPARATOR
Intervention: Control condition (disclosure of assigned experimental condition)
Number of subjects: 134
Study 15652836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal-hinged ACS microkeratome (NH) with 130 microm depth plate
Number of subjects: 40
Study 15652836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal-hinged ACS microkeratome (NH) with 160 microm depth plate
Number of subjects: 40
Study 15652836 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior-hinged Hansatome microkeratome (SH) with 160 microm depth plate
Number of subjects: 40
Study 15652836 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior-hinged Hansatome microkeratome (SH) with 180 microm depth plate
Number of subjects: 40
Study 11890185 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 703
Study 11890185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 10217889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mothers encouraged to engage in narrative conversation)
Number of subjects: 20
Study 10217889 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 20
Study 7734257 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 20 mg administered before operation
Number of subjects: 0
Study 7734257 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg at induction and 10 mg on closure of the peritoneum
Number of subjects: 0
Study 2040933 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (100 units/kg twice each week for 6 weeks)
Number of subjects: 20
Study 2040933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2040933 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 20
Study 6120793 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administration
Number of subjects: 3837
Study 6120793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 31844951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 111
Study 31844951 — intervention group
Group type: EXPERIMENTAL
Intervention: RF ablation
Number of subjects: 111
Study 30938860 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily)
Number of subjects: 105
Study 30938860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined calcium and vitamin D3
Number of subjects: 105
Study 30938860 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 alone
Number of subjects: 105
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (mainly antipyretic analgesics, nonsteroidal anti-inflammatory drugs, opioids)
Number of subjects: 2922
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidurals in abdominal surgery
Number of subjects: 2922
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute opioid treatments
Number of subjects: 2922
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional analgesia
Number of subjects: 2922
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 2922
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain (>7) and/or chronic opioid consumption before surgery
Number of subjects: 2922
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibia/fibula and foot surgeries (ORT), gastric, small intestine, and anterior abdominal wall procedures (GEN)
Number of subjects: 2922
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (intravenous morphine)
Number of subjects: 2922
Study 28619696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment and information
Number of subjects: 2922
Study 25759961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (10 mg Zn/day) and venous zinc administration (0.06537 mg Zn/kg of body weight) in the experimental group.
Number of subjects: 40
Study 25759961 — intervention group
Group type: COMPARATOR
Intervention: Control group using 10% sorbitol.
Number of subjects: 40
Study 23545928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone-free skin brightening product
Number of subjects: 18
Study 23545928 — intervention group
Group type: COMPARATOR
Intervention: 4% HQ cream
Number of subjects: 18
Study 21042875 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil (N = 36; 3.0 g/day, EPA + DHA = 543 mg)
Number of subjects: 113
Study 21042875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (N = 40; 1.8 g/day, EPA + DHA = 864 mg)
Number of subjects: 113
Study 21042875 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 37)
Number of subjects: 113
Study 18719059 — intervention group
Group type: COMPARATOR
Intervention: Aminoguanidine (iNOS inhibitor)
Number of subjects: 0
Study 17370486 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongwan (CV 12) with deep needling
Number of subjects: 276
Study 17370486 — intervention group
Group type: COMPARATOR
Intervention: Climetidine (control group)
Number of subjects: 276
Study 15307342 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training
Number of subjects: 1294
Study 15307342 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 1294
Study 11266238 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline-Pirquet test (aP)
Number of subjects: 585
Study 11266238 — intervention group
Group type: COMPARATOR
Intervention: Mantoux test with PPD 2 TU (M2)
Number of subjects: 585
Study 11266238 — intervention group
Group type: COMPARATOR
Intervention: Mantoux test with PPD 5 TU (M5)
Number of subjects: 585
Study 11266238 — intervention group
Group type: COMPARATOR
Intervention: PPD 2 TU-Rhoditest (Rh)
Number of subjects: 585
Study 9354206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral benzocaine 0.75% solution (n = 14)
Number of subjects: 26
Study 9354206 — intervention group
Group type: COMPARATOR
Intervention: Benzocaine-free solvent (placebo, n = 12)
Number of subjects: 26
Study 7872981 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + diet (E) group
Number of subjects: 16
Study 7872981 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 16
Study 3046105 — intervention group
Group type: COMPARATOR
Intervention: Phenylpropanolamine (PPA) alone
Number of subjects: 36
Study 3046105 — intervention group
Group type: COMPARATOR
Intervention: Estriol alone
Number of subjects: 36
Study 3046105 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol and PPA in combination
Number of subjects: 36
Study 29250706 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic saline (AS, pH 5)
Number of subjects: 28
Study 29250706 — intervention group
Group type: COMPARATOR
Intervention: Neutral saline (NS, pH 7.4)
Number of subjects: 28
Study 27412192 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic per-conditioning (four cycles of electronic tourniquet inflation and deflation for 5 minutes each)
Number of subjects: 200
Study 27412192 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 200
Study 27412192 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic per-conditioning
Number of subjects: 200
Study 24103188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis Bf-6 (LMG 24384) yogurt
Number of subjects: 68
Study 24103188 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 68
Study 22177808 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted sites with an anorganic xenograft plus a membrane
Number of subjects: 28
Study 22177808 — intervention group
Group type: COMPARATOR
Intervention: Nongrafted sites
Number of subjects: 28
Study 20831528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 5 mg/kg/h for 6 hours for 6 successive days
Number of subjects: 37
Study 20831528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 37
Study 20831528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 37
Study 18711190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Number of subjects: 0
Study 18711190 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 0
Study 18711190 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2 (IL-2)
Number of subjects: 0
Study 15867559 — intervention group
Group type: EXPERIMENTAL
Intervention: C-labeled nandrolone (25 mg dose, followed by a second identical dose 24 hours later)
Number of subjects: 34
Study 15867559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12409588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spiral computed tomography (CT)
Number of subjects: 304
Study 12409588 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 304
Study 9861520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg daily
Number of subjects: 69
Study 9861520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9861520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 69
Study 8583024 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual methods for assessing vital plaque
Number of subjects: 12